Glycine and a Glycine Dehydrogenase (GLDC) SNP as Citalopram/Escitalopram Response Biomarkers in Depression: Pharmacometabolomics-Informed Pharmacogenomics
- 24 November 2010
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 89 (1), 97-104
- https://doi.org/10.1038/clpt.2010.250
Abstract
Major depressive disorder (MDD) is a common psychiatric disease. Selective serotonin reuptake inhibitors (SSRIs) are an important class of drugs used in the treatment of MDD. However, many patients do not respond adequately to SSRI therapy. We used a pharmacometabolomics‐informed pharmacogenomic research strategy to identify citalopram/escitalopram treatment outcome biomarkers. Metabolomic assay of plasma samples from 20 escitalopram remitters and 20 nonremitters showed that glycine was negatively associated with treatment outcome (P = 0.0054). This observation was pursued by genotyping tag single‐nucleotide polymorphisms (SNPs) for genes encoding glycine synthesis and degradation enzymes, using 529 DNA samples from SSRI‐treated MDD patients. The rs10975641 SNP in the glycine dehydrogenase (GLDC) gene was associated with treatment outcome phenotypes. Genotyping for rs10975641 was carried out in 1,245 MDD patients in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, and its presence was significant (P = 0.02) in DNA taken from these patients. These results highlight a possible role for glycine in SSRI response and illustrate the use of pharmacometabolomics to “inform” pharmacogenomics. Clinical Pharmacology & Therapeutics (2011) 89 1, 97–104. doi: 10.1038/clpt.2010.250Keywords
This publication has 37 references indexed in Scilit:
- A Genomewide Association Study of Citalopram Response in Major Depressive DisorderBiological Psychiatry, 2009
- Opioid use affects antioxidant activity and purine metabolism: preliminary resultsHuman Psychopharmacology: Clinical and Experimental, 2009
- Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophreniaMolecular Psychiatry, 2009
- Breast Cancer Risk Reduction and Membrane-Bound Catechol O-Methyltransferase Genetic PolymorphismsCancer Research, 2008
- SLC6A4 variation and citalopram responseAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2008
- Metabolomics: A Global Biochemical Approach to Drug Response and DiseaseAnnual Review of Pharmacology and Toxicology, 2008
- Genomic deletion within GLDC is a major cause of non-ketotic hyperglycinaemiaJournal of Medical Genetics, 2006
- Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant TreatmentAmerican Journal of Human Genetics, 2006
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences, 2003